

Pharmacokinetics in Drug Development

Peter L. Bonate • Danny R. Howard
Editors

Pharmacokinetics in Drug Development

Problems and Challenges in Oncology,
Volume 4

 Springer

Editors

Peter L. Bonate
Pharmacokinetics/Modeling/Simulation
2N.184 Astellas
Global Clinical Pharmacology and
Exploratory Development
Northbrook, IL, USA

Danny R. Howard
Oncology Clinical Pharmacology
Novartis
East Hanover, NJ, USA

ISBN 978-3-319-39051-2 ISBN 978-3-319-39053-6 (eBook)
DOI 10.1007/978-3-319-39053-6

Library of Congress Control Number: 2004051818

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG Switzerland

Contents

1 Overview of Oncology Drug Development	1
Laeq Malik and Steven Weitman	
2 Overview of Oncology Biomarkers	29
Mitsukuni Suenaga, Heinz-Josef Lenz, and Stefan J. Scherer	
3 A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond	39
Peng Zou, Sau Lee, Min Li, Lawrence Yu, and Duxin Sun	
4 Controversies in Oncology: Size Based vs. Fixed Dosing	59
Peter L. Bonate	
5 Clinical QTc Assessment in Oncology	77
Margaret R. Britto and Nenad Sarapa	
6 Expediting Drug Development: Breakthrough Therapy Designation	107
Carmen Ladner	
7 Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors.....	121
Ana Ruiz-Garcia and Shinji Yamazaki	
8 Combination Development.....	151
Annie St-Pierre, Maribel Reyes, and Vincent Duval	
9 Role of Pharmacokinetics: Pharmacodynamics in Biosimilar Assessment	175
Antonio da Silva and Didier Renard	
10 Pharmacokinetics and Pharmacogenetics of Metronomics	189
Nicolas André, Joseph Ciccolini, Marie Amélie Heng, and Eddy Pasquier	

**11 Modeling Tumor Growth in Animals and Humans:
An Evolutionary Approach** 209
Dean C. Bottino and Arijit Chakravarty

**12 Practical Considerations for Clinical Pharmacology in Drug
Development: A Survey of 44 FDA Oncology Approvals** 237
Danny R. Howard

**13 New Advancements in Exposure-Response Analysis
to Inform Regulatory Decision Making** 303
Liang Zhao, Li Hongshan, Anshu Marathe, Jingyu (Jerry) Yu,
Dinko Rekić, Nitin Mehrotra, Vikram Sinha, and Yaning Wang

Erratum to:..... E1

Index..... 319

The original version of this book was revised. An erratum to this book can be found at DOI [10.1007/978-3-319-39053-6_14](https://doi.org/10.1007/978-3-319-39053-6_14)

Contributors

Nicolas André Department of Pediatric Hematology and Oncology, AP-HM, La Timone Hospital, Marseille, France

Peter L. Bonate Pharmacokinetics/Modeling/Simulation 2N.184 Astellas, Global Clinical Pharmacology and Exploratory Development, Northbrook, IL, USA

Dean C. Bottino Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Margaret R. Britto Pharmacokinetics/Pharmacodynamics Quintiles, Inc., Overland Park, KS, USA

Arijit Chakravarty Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Joseph Ciccolini SMARTc Aix Marseille Université, INSERM, Center for Research in Oncobiology and Oncopharmacology UMR_S 911, Marseille, France

Vincent Duval Novartis Pharma AG, Basel, Switzerland

Marie Amélie Heng Department of Pediatric Hematology and Oncology, AP-HM, La Timone Hospital, Marseille, France

Li Hongshan Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Danny R. Howard Novartis Pharmaceuticals, East Hanover, NJ, USA

Carmen Ladner Five Prime Therapeutics Inc., South San Francisco, CA, USA

Sau Lee Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Min Li Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Heinz-Josef Lenz USC Norris Cancer Center, Los Angeles, CA, USA

Laeq Malik Capital Region Cancer Centre, The Canberra Hospital, Garran, Australia

Anshu Marathe Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Nitin Mehrotra Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Eddy Pasquier Center for Research in Oncobiology and Oncopharmacology UMR_S 911 Aix Marseille Université, Marseille, France
Metronomics Global Health Initiative, Marseille, France

Dinko Rekić Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Didier Renard Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland

Maribel Reyes Novartis Pharma AG, Basel, Switzerland

Ana Ruiz-Garcia Clinical Pharmacology, Global Research and Development Pfizer, San Diego, CA, USA

Nenad Sarapa Clinical Sciences Oncology, Bayer Healthcare, Inc., Whippany, NJ, USA

Stefan J. Scherer VP Global Head Correlative Science, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, USA

Antonio da Silva Preclinical Development, Hexal AG, A Sandoz Company Part of the Novartis Group, Holzkirchen, Germany

Vikram Sinha Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Annie St-Pierre Novartis Pharma AG, Basel, Switzerland

Duxin Sun Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI, USA

Mitsukuni Suenaga Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan

Yaning Wang Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Steven Weitman Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, USA

Shinji Yamazaki Pharmacokinetics Drug Metabolism, WW Research and Development, Pfizer, San Diego, CA, USA

Lawrence Yu Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Jingyu (Jerry) Yu Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Liang Zhao Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

Peng Zou Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

About the Editors

Peter L. Bonate has acquired over 22 years of industrial experience: 19 years as a clinical pharmacologist/pharmacokineticist and 3 years in drug metabolism and bioanalysis. He is currently Executive Director of Pharmacokinetics, Modeling, and Simulation at Astellas. He received his Ph.D. from Indiana University in Medical Neurobiology with an emphasis on the pharmacokinetics of drugs of abuse. He also received an M.S. in Statistics from the University of Idaho and an M.S. in Pharmacology from Washington State University. He is a Fellow of the American College of Clinical Pharmacology and American Association of Pharmaceutical Scientists (AAPS). Within AAPS, he was a founder of the Pharmacometrics focus group, was chair of the Clinical Pharmacology and Translational Research Section, and was AAPS Fellows Committee Chair. Dr. Bonate is a recipient of the AAPS Research Achievement Award in Clinical Pharmacology and Translational Research. He is currently an Associate Editor of the *Journal of Pharmacokinetics and Pharmacodynamics*. He has served or currently serves on the editorial boards for the *Journal of Clinical Pharmacology*, *Pharmaceutical Research*, and the *AAPS Journal*. He has written more than 60 peer-reviewed publications and is author of the books *Pharmacokinetic-Pharmacodynamic Modeling and Simulation, 2nd edition* and *Be a Model Communicator (and sell your models to anyone)*.

Danny R. Howard received his Bachelor of Science degree in Pharmacy, and Ph.D. from the University of Missouri in Kansas City. He joined Novartis as the Head of Global Pharmacokinetics and Pharmacodynamics and is currently the Vice President of Oncology Clinical Pharmacology for the Novartis Oncology Business Unit. He began working in the pharmaceutical industry first as a biopharmaceutics consultant and then as a pharmaceutical scientist for Marion Merrell Dow, Hoechst Marion Roussel, Aventis, and Quintiles. His career has included responsibilities in both clinical and nonclinical pharmacokinetics and pharmacodynamics, bioanalytics, pharmaceutical business operations, and drug metabolism and pharmacokinetics. He has worked with numerous worldwide new drug submissions supporting both large and small molecules, within and outside the area of oncology. He was a charter member of the Missouri Biotech Association and served as its first Board Chairman.

Dr. Howards is also a member of American Association of Pharmaceutical Scientists (AAPS), American Society for Clinical Pharmacology and Therapeutics (ASCPT), and American Society of Clinical Oncology (ASCO). He is an accomplished author or coauthor of over 50 scientific publications and presentations in the area of clinical pharmacology and pharmaceutical sciences.